MedTrace Logo

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

NCT06609161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-09-27

No results posted yet for this study

Summary

The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.

Conditions

  • Healthy

Interventions

DRUG

Tedizolid Phosphate Oral Formulation 1 (Reference)

Formulation 1 (FM1) powder for oral suspension.

DRUG

Tedizolid Phosphate Oral Formulation 2 (Test)

Formulation 2 (FM2) powder for oral suspension.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-16
Primary Completion
2024-08-08
Completion
2024-08-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06609161 on ClinicalTrials.gov